The major objective of the study was the measurement of the cost- effectiveness of olanzapine treatment in Hungary. To compare the short and long term clinical outcomes and direct costs of treatment, the authors adapted the decision based Markov model. Adaptation process was divided into different steps: the definition of the units of costs, the adaptation of resource utilization in schizophrenia in Hungary, and revisiting of variables of clinical effectiveness. Data to calculate costs and to measure utilization were collected from sources like Hungarian Health Insurance Fund (HIF) and National Institute of Psychiatry and Neurology. Missing information were substituted by consensus results of a nominal group of the Hungarian specialists. Costs were evaluated from the viewpoint of HIF. Only direct costs of treatment and rehabilitation were taken into consideration based on 1998 data, and projected to several years ahead with the help of the adapted Markov model. The clinical parameters used by the model were based on the results of published double blind international trials. Taking into consideration the direct costs of schizophrenia treatment paid by HIF, despite the higher acquisitions costs of olanzapine, initiation of olanzapine treatment rather than haloperidol has the same or better health outcome, for the same unit payment by HIF in Hungary. Furthermore both short- and long- term, our results support the major findings of the literature i.e. cost- effectiveness of olanzapine treatment of schizophrenia is similar or more favorable than haloperidol treatment. Based on the results of our Hungarian study, olanzapine is a cost-effective alternative treatment of schizophrenia.
|Translated title of the contribution||Comparative evaluation of the cost-effectiveness of olanzapine treatment of haloperidol treatment with Markov-modeling in Hungary|
|Number of pages||13|
|Publication status||Published - Jan 1 2000|
ASJC Scopus subject areas